Vivos Reports Momentum Since FDA Clearance of Oral Appliances for Severe OSA
In its fourth-quarter and full-year 2023 highlights, Vivos Therapeutics reported positive business momentum following receiving US Food and Drug Administration clearance for its oral appliances to treat severe obstructive sleep apnea last November.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
